Additionally, RT promotes immunogenic cell death and increases CD8+ T cell infiltration, and thus, the combined use of Azeliragon and RT synergistically creates a tumor microenvironment potentially more amenable to immune-mediated eradication [36,45,46]. The gene discussed is CD8A; the disease is neoplasm.